Drug Profile
Research programme: neuroinflammatory and neurodegenerative disease therapeutics - Neurotech Pharma
Alternative Names: NT CC 017; NT KO 009; NT KO 012Latest Information Update: 29 Sep 2023
Price :
$50
*
At a glance
- Originator Neurotec Pharma
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Inflammation; Neurodegenerative disorders
Most Recent Events
- 29 Sep 2023 Discontinued - Preclinical for Inflammation in Spain (unspecified route)
- 29 Sep 2023 Discontinued - Preclinical for Neurodegenerative disorders in Spain (unspecified route)
- 28 Dec 2020 No recent reports of development identified for preclinical development in Inflammation in Spain